-
公开(公告)号：US20220168410A1
公开(公告)日：2022-06-02
申请号：US17672126
申请日：2022-02-15
Applicant: Pfizer Inc.
Inventor： Robert G.K. Donald , Annaliesa Sybil Anderson , Laurent Oliver Chorro , Jianxin Gu , Jin-Hwan Kim , Srinivas Kodali , Jason Arnold Lotvin , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , Ling Chu , Scott Ellis Lomberk , Karen Kiyoko Takane , Nishith Merchant , Wei Chen
IPC: A61K39/108 , C08B37/00 , A61P31/04 , A61P37/04
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
-
公开(公告)号：US20170182151A1
公开(公告)日：2017-06-29
申请号：US15385611
申请日：2016-12-20
Applicant: Pfizer Inc.
Inventor： Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , C07K14/005 , C12N7/00
CPC classification number: A61K39/155 , A61K39/12 , A61K2039/575 , C07K14/005 , C07K2319/02 , C07K2319/21 , C07K2319/22 , C07K2319/40 , C07K2319/70 , C07K2319/735 , C12N7/00 , C12N2760/18522 , C12N2760/18534 , C12N2760/18571
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
公开(公告)号：US09950058B2
公开(公告)日：2018-04-24
申请号：US15385611
申请日：2016-12-20
Applicant: Pfizer Inc.
Inventor： Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , C07K14/135 , C12N15/01 , C07K14/005 , C12N7/00 , A61K39/12 , A61K39/00
CPC classification number: A61K39/155 , A61K39/12 , A61K2039/575 , C07K14/005 , C07K2319/02 , C07K2319/21 , C07K2319/22 , C07K2319/40 , C07K2319/70 , C07K2319/735 , C12N7/00 , C12N2760/18522 , C12N2760/18534 , C12N2760/18571
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
公开(公告)号：US09777076B2
公开(公告)日：2017-10-03
申请号：US14412646
申请日：2013-07-03
Applicant: Pfizer Inc.
Inventor： Robert G. K. Donald , Srinivas Kodali , Evguenii Vinogradov
IPC: A61K31/715 , A61K47/48 , C08B37/00 , C08H1/00
CPC classification number: C08B37/006 , A61K31/715 , A61K47/64 , A61K47/646 , C08H1/00
Abstract: The invention relates to novel saccharides and uses thereof. In one aspect, the invention relates to a saccharide having a legionaminic acid moiety, a N-acetylgalactosamine moiety, a galactose moiety, and a glucose moiety. In another aspect, the invention relates to a saccharide having an altruronic acid moiety, a fucose moiety, and a glucose moiety. In yet another aspect, the invention relates to a saccharide having a repeating unit of a glycerol phosphate moiety and a glucose moiety, wherein the saccharide is from Enterococcus faecium. In a further aspect, the invention relates to a saccharide having a repeating unit of -6-β-D-Fruf-2, wherein Fru is a fructose moiety, wherein the saccharide is from Enterococcus faecium. In another aspect, the invention relates to an isolated antibody or fragment thereof that specifically binds to a saccharide described herein and uses thereof.
-
公开(公告)号：US20200061177A1
公开(公告)日：2020-02-27
申请号：US16534457
申请日：2019-08-07
Applicant: Pfizer Inc.
Inventor： Robert G.K. Donald , Annaliesa Sybil Anderson , Laurent Oliver Chorro , Jianxin Gu , Jin-Hwan Kim , Srinivas Kodali , Jason Arnold Lotvin , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , Ling Chu , Scott Ellis Lomberk , Karen Kiyoko Takane , Nishith Merchant , Wei Chen
IPC: A61K39/108 , C08B37/00 , A61P37/04 , A61P31/04
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
-
Patent Agency Ranking
公开(公告)号：US20190125861A1
公开(公告)日：2019-05-02
申请号：US16242799
申请日：2019-01-08
Applicant: Pfizer Inc.
Inventor： Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , C07K14/005 , A61K39/12 , C12N7/00
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
公开(公告)号：US20160002361A1
公开(公告)日：2016-01-07
申请号：US14412646
申请日：2013-07-03
Applicant: Pfizer Inc.
Inventor： Robert G. K. Donald , Srinivas Kodali , Evguenii Vinogradov
IPC: C08B37/00 , A61K31/715 , A61K47/48
CPC classification number: C08B37/006 , A61K31/715 , A61K47/64 , A61K47/646 , C08H1/00
Abstract: The invention relates to novel saccharides and uses thereof. In one aspect, the invention relates to a saccharide having a legionaminic acid moiety, a N-acetylgalactosamine moiety, a galactose moiety, and a glucose moiety. In another aspect, the invention relates to a saccharide having an altruronic acid moiety, a fucose moiety, and a glucose moiety. In yet another aspect, the invention relates to a saccharide having a repeating unit of a glycerol phosphate moiety and a glucose moiety, wherein the saccharide is from Enterococcus faecium. In a further aspect, the invention relates to a saccharide having a repeating unit of -6-β-D-Fruf-2, wherein Fru is a fructose moiety, wherein the saccharide is from Enterococcus faecium. In another aspect, the invention relates to an isolated antibody or fragment thereof that specifically binds to a saccharide described herein and uses thereof.
Abstract translation: 本发明涉及新型糖类及其用途。 一方面，本发明涉及具有军团氨基酸部分，N-乙酰半乳糖胺部分，半乳糖部分和葡萄糖部分的糖。 另一方面，本发明涉及具有丙二醛酸部分，岩藻糖部分和葡萄糖部分的糖。 另一方面，本发明涉及具有甘油磷酸酯部分和葡萄糖部分的重复单元的糖类，其中所述糖类来自屎肠球菌。 另一方面，本发明涉及一种具有重量单位为6-bgr-D-Fruf-2的糖类，其中Fru是果糖部分，其中糖类来自屎肠球菌。 另一方面，本发明涉及与本文所述的糖类及其用途特异性结合的分离的抗体或其片段。
-
公开(公告)号：US20230321212A1
公开(公告)日：2023-10-12
申请号：US18042561
申请日：2021-08-23
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Robert George Konrad Donald , Julio Cesar Hawkins , Srinivas Kodali , Raphael Simon
CPC classification number: A61K39/092 , A61P37/04 , A61K2039/6031
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20210023200A1
公开(公告)日：2021-01-28
申请号：US17060944
申请日：2020-10-01
Applicant: Pfizer Inc.
Inventor： Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , A61K39/12 , C07K14/005 , C12N7/00
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
公开(公告)号：US10238732B2
公开(公告)日：2019-03-26
申请号：US15896871
申请日：2018-02-14
Applicant: Pfizer Inc.
Inventor： Ye Che , Philip Ralph Dormitzer , Alexey Vyacheslavovich Gribenko , Luke David Handke , Avvari Krishna Prasad , Xiayang Qiu , Mark Edward Ruppen , Xi Song , Kena Anne Swanson , Srinivas Kodali , Xin Xu , KariAnn Sweeney Efferen , Ping Cai , Kristin Rachael Tompkins , Lorna del Pilar Nunez
IPC: A61K39/155 , C07K14/135 , C12N15/01 , C07K14/005 , C12N7/00 , A61K39/12 , A61K39/00
Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.019 seconds)
